Iradimed Corp (NASDAQ:IRMD) VP Sells $20,060.00 in Stock

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 1,000 shares of Iradimed stock in a transaction on Monday, June 10th. The shares were sold at an average price of $20.06, for a total value of $20,060.00. Following the sale, the vice president now directly owns 2,368 shares of the company’s stock, valued at approximately $47,502.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Brent Johnson also recently made the following trade(s):

  • On Wednesday, June 12th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.57, for a total transaction of $61,710.00.
  • On Friday, June 7th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.00, for a total transaction of $20,000.00.
  • On Thursday, May 23rd, Brent Johnson sold 4,000 shares of Iradimed stock. The stock was sold at an average price of $21.78, for a total value of $87,120.00.
  • On Monday, May 20th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $22.53, for a total value of $45,060.00.
  • On Friday, May 17th, Brent Johnson sold 3,000 shares of Iradimed stock. The shares were sold at an average price of $21.83, for a total transaction of $65,490.00.

IRMD traded up $0.04 during trading hours on Wednesday, hitting $20.98. 25,741 shares of the company’s stock were exchanged, compared to its average volume of 62,279. Iradimed Corp has a 12-month low of $18.40 and a 12-month high of $38.78. The company has a market cap of $233.63 million, a P/E ratio of 48.79 and a beta of 1.78. The company has a quick ratio of 8.63, a current ratio of 9.48 and a debt-to-equity ratio of 0.06.

Iradimed (NASDAQ:IRMD) last announced its earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, hitting the consensus estimate of $0.11. Iradimed had a net margin of 23.00% and a return on equity of 13.98%. The firm had revenue of $8.44 million for the quarter, compared to the consensus estimate of $8.38 million. Research analysts forecast that Iradimed Corp will post 0.64 earnings per share for the current year.

IRMD has been the topic of several recent research reports. BidaskClub cut shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th. Zacks Investment Research upgraded shares of Iradimed from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a research note on Tuesday, May 7th. Finally, ValuEngine downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Iradimed has an average rating of “Buy” and an average target price of $31.50.

A number of institutional investors and hedge funds have recently made changes to their positions in IRMD. Marshall Wace LLP purchased a new stake in shares of Iradimed in the 1st quarter valued at approximately $241,000. Charles Schwab Investment Management Inc. acquired a new stake in Iradimed during the 1st quarter worth $221,000. Renaissance Technologies LLC boosted its stake in Iradimed by 8.0% during the 1st quarter. Renaissance Technologies LLC now owns 346,200 shares of the medical equipment provider’s stock worth $9,725,000 after purchasing an additional 25,700 shares during the period. AQR Capital Management LLC boosted its stake in Iradimed by 73.4% during the 1st quarter. AQR Capital Management LLC now owns 15,764 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 6,673 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Iradimed by 56.9% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 13,188 shares of the medical equipment provider’s stock worth $370,000 after purchasing an additional 4,780 shares during the period. 23.53% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Iradimed Corp (NASDAQ:IRMD) VP Sells $20,060.00 in Stock” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2019/06/12/iradimed-corp-nasdaqirmd-vp-sells-20060-00-in-stock.html.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Recommended Story: Stock Symbols and CUSIP Explained

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply